GeoVax Labs Inc. (NASDAQ: GOVX) outlined its strategy to address supply constraints in the global orthopoxvirus vaccine market with its GEO-MVA vaccine candidate, according to a company statement.

The biotechnology company said the mpox and smallpox vaccine market operates as a procurement-driven market supported by national stockpile programs, global health organization purchases, and outbreak-driven demand. The market currently relies on a single commercial supplier of MVA vaccines, creating limited surge capacity during outbreaks and repeated depletion of government stockpiles.

GeoVax stated that public disclosures indicate the mpox and smallpox vaccine market generates hundreds of millions of dollars in annual procurement. The company said this includes multiyear purchasing frameworks and forward-looking supply agreements.

The company's GEO-MVA vaccine candidate uses the established MVA platform and follows a defined regulatory pathway based on immuno-bridging to an approved MVA vaccine. GeoVax plans to initiate a Phase 3 trial for GEO-MVA in 2026.

"The mpox and smallpox vaccine market is not a future construct, it is an active, procurement-driven market with recurring demand and increasing strategic importance," said David Dodd, Chairman and Chief Executive Officer of GeoVax.

GeoVax believes governments and public health agencies are prioritizing establishment of additional MVA vaccine supply sources and expansion of domestic manufacturing capacity to reduce dependence on single-source providers.

The company said recent mpox outbreaks across multiple continents have reinforced the need for sustained vaccine supply beyond emergency response cycles. GeoVax stated that GEO-MVA is positioned for both civilian and biodefense procurement channels.